Basal forebrain

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, April 1, 2024
Lewy body, Research, GBA, Administration, Plasma, Conference, MRI, DLB, GFAP, Basal forebrain, Patient, Journal, Chairperson, Sale, TID, Manuscript, Public expenditure, Biomarker, Glial fibrillary acidic protein, MD, University College London, Atrophy, Publication, Frontotemporal dementia, Alpha-synuclein, NIA, Research and development, Vertex Pharmaceuticals, Axonal transport, Dementia, CRVO

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Moreover, the neflamapimod treatment effects on GFAP were correlated to clinical outcomes, assessed by the CDR-SB.
  • Cash Position: As of December 31, 2023, CervoMed had $7.8 million in cash and cash equivalents as compared to $4.1 million as of December 31, 2022.
  • This increase was attributed to the RewinD-LB Phase 2b clinical study in DLB which began in the first quarter of 2023.
  • Net Loss: Net Loss was $2.2 million for the year ended December 31, 2023, compared to a net loss of $5.8 million for year ended December 31, 2022.

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Retrieved on: 
Tuesday, March 5, 2024
Axonal transport, Tauopathy, Neuron, CRVO, Cell biology, DLB, Plasma, Medical laboratory, MB, Phosphorylation, Overalls, FTD, GS, Vrije Universiteit Amsterdam, Publication, MAPK, Glial fibrillary acidic protein, GFAP, Axon, Brain, CNR, IW, EM, SDL, UCL, RAF kinase, Alpha-synuclein, Conference, Biomarker, AG, Lewy body, GBA, MD, Neurochemistry, PDF, JC, CP, Patient, Dementia, Basal forebrain, JA, Medical imaging

BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the presentation of biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies (DLB), demonstrating that neflamapimod reduces plasma levels of glial fibrillary acidic protein (GFAP) compared placebo, and that the effects of neflamapimod on GFAP were inversely correlated to change in CDR-SB (reduction in GFAP associated with improvement in CDR-SB, and increase in GFAP associated with worsening in CDR-SB). These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024. In addition, academic researchers from UCL will be presenting data in a separate poster at the meeting demonstrating that p38MAPK inhibition, including with neflamapimod specifically, improves tau-induced axonal transport defects both in vitro and in a tauopathy mouse model.

Key Points: 
  • These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024.
  • “The effects on GFAP, particularly the association between GFAP response and clinical outcomes, further support that neflamapimod is clinically efficacious in patients with DLB,” said John Alam, MD, Chief Executive Officer of CervoMed.
  • A PDF copy of the GFAP poster presentation will be available on the “ Presentations and Publications ” section of the CervoMed website.
  • Title: NEW INSIGHTS IN THE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

Retrieved on: 
Tuesday, October 24, 2023
Alzheimer's disease, CRVO, Attention, Plasma, AD, Three-body problem, Neurology, MD, Publication, CNS, DLB, HIV disease progression rates, Basal forebrain, Ganz railcar (Ferrocarriles Vascongados, short version), Dementia, Nature Communications, American Academy, Drug development, Brain, Lewy body, Patient, Molecular Neurodegeneration, Pharmaceutical industry, Medical imaging

BOSTON, Oct. 24, 2023 /PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the publication of the following two articles that support advancing neflamapimod as a disease-modifying treatment for Dementia with Lewy Bodies (DLB) and Alzheimer's Disease (AD):

Key Points: 
  • Neurology® is the medical journal of the American Academy of Neurology.
  • The journal has released the final publication, including a Short Version in print, of the article that was the subject of a press release from CervoMed dated September 6th, 2023.
  • Alam J and Nixon RA, Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come.
  • "As reported in Nature Communications last year, the primary analysis of the phase 2a study of DLB showed neflamapimod significantly improved dementia severity and motor function.

EIP Pharma Announces Presentation of Neuroimaging Data Exhibiting Potential Effects of Neflamapimod on Cholinergic Structure and Function at AD/PD™ 2023

Retrieved on: 
Monday, April 3, 2023
Nucleus, Neuron, International Conference on Information Systems Security and Privacy, Atrophy, Alzheimer's disease, EOT, Swedish Exhibition & Congress Centre, NBM, Basal forebrain, Biomarker, DGM, MRI, Magnetic resonance imaging, MD, AD, Conference, Structure, MAP, Medical imaging, Neuroscience, Anatomy, Patient

BOSTON, April 3, 2023 /PRNewswire/ -- EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases, today announced the oral presentation by academic investigators from the Amsterdam University Medical Center of neuroimaging results from a phase 2a clinical study in patients with early Alzheimer's disease (AD) at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™) 2023, which took place virtually and in person March 28 – April 1, 2023, in Gothenburg, Sweden.

Key Points: 
  • Structural and MRI assessments had been conducted at baseline and following 12 weeks of treatment with neflamapimod.
  • The potential regression of atrophy and recovery of function in neflamapimod-treated patients in this study suggests a restoration of cholinergic neurons in the NbM and are supportive of data generated in previous preclinical studies that demonstrated neflamapimod reversed the neurodegenerative process in the basal forebrain cholinergic system.
  • "We are encouraged by these findings and are pleased to share these important results with the medical and scientific community."
  • Title: Effects of the p38-Alpha Kinase Inhibitor Neflamapimod on the Basal Forebrain in Patients, Assessed by Structural MRI
    Speaker: Chen-Pei Lin, Department of Anatomy and Neurosciences, Amsterdam University Medical Center
    Location: Gothenburg, Sweden (Swedish Exhibition & Congress Centre; Hall F4+F5)

EIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with Lewy Bodies: Nature Communications

Retrieved on: 
Wednesday, September 21, 2022
Professional Services, Health, Clinical Trials, Banking, Pharmaceutical, Biotechnology, Acetylcholine, Therapy, Neurodegeneration, Lists of diseases, Lewy body, Average absolute deviation, MAP, Ageing, FDA, MD, Food, Basal forebrain, Research, Brain, Government budget balance, Even and odd functions, Company, EIP, Nathan, Cognition, DLB, Patient, Neurological disorder, Attention, Timed Up and Go test, Center, TUG, Doctor of Philosophy, Nature Communications, Body, Drug development, CNS, NTB, Neuron, Lewy, Disease, Pharmaceutical industry, Dementia

The animal studies in the publication show that neflamapimod reduces Rab5 activity and reverses the neurodegenerative process in the basal forebrain.

Key Points: 
  • The animal studies in the publication show that neflamapimod reduces Rab5 activity and reverses the neurodegenerative process in the basal forebrain.
  • These combined pre-clinical and clinical results provide a foundation for a confirmatory, hypothesis-testing Phase 2b clinical study evaluating neflamapimod for DLB.
  • The data published today provide us confidence to progress neflamapimod into a confirmatory Phase 2b clinical trial in Dementia with Lewy Bodies.
  • et al., Preclinical and Randomized Clinical Evaluation of the p38 Kinase Inhibitor Neflamapimod for Basal Forebrain Cholinergic Degeneration, Nature Communications, 13, Article number: 5308 (2022).

Clinical Trial in Dementia with Lewy Bodies Used Cogstate Digital Assessments and Data Quality Services to Support the Evaluation of Neflamapimod

Retrieved on: 
Wednesday, December 1, 2021
Patient, Caregiver, Neuron, Detection, ASX, Clinical trial, Cognition, Neurodegeneration, Basal forebrain, Physician, Research, GLOBE, NPI, Body, Neuroscience, TUG, DLB, Disease, Medical imaging, Pharmaceutical industry

The company announced final results of the trial, which demonstrated neflamapimod treatment led to significant improvement relative to placebo in cognition, functional mobility and dementia progression in patients with DLB.

Key Points: 
  • The company announced final results of the trial, which demonstrated neflamapimod treatment led to significant improvement relative to placebo in cognition, functional mobility and dementia progression in patients with DLB.
  • DLB is the second most common form of dementia, and currently there are no treatments available for the disease.
  • The AcendD-LB trial results represent a possible breakthrough in development of a therapeutic candidate for individuals impacted by DLB worldwide.
  • Cogstate pioneers rapid, reliable and highly sensitive digital cognitive testing technologies, and delivers data quality services for clinical outcome assessments that combine scientific insights, innovative operational approaches and advanced analytics.